Literature DB >> 35025696

Degradation of the NOTCH intracellular domain by elevated autophagy in osteoblasts promotes osteoblast differentiation and alleviates osteoporosis.

Gota Yoshida1, Tsuyoshi Kawabata1,2, Hyota Takamatsu3, Shotaro Saita1,4, Shuhei Nakamura1,4, Keizo Nishikawa5,6, Mari Fujiwara1,4, Yusuke Enokidani1,4, Tadashi Yamamuro1,4, Keisuke Tabata1,4, Maho Hamasaki1,4, Masaru Ishii5, Atsushi Kumanogoh3, Tamotsu Yoshimori1,4.   

Abstract

Maintenance of bone integrity is mediated by the balanced actions of osteoblasts and osteoclasts. Because macroautophagy/autophagy regulates osteoblast mineralization, osteoclast differentiation, and their secretion from osteoclast cells, autophagy deficiency in osteoblasts or osteoclasts can disrupt this balance. However, it remains unclear whether upregulation of autophagy becomes beneficial for suppression of bone-associated diseases. In this study, we found that genetic upregulation of autophagy in osteoblasts facilitated bone formation. We generated mice in which autophagy was specifically upregulated in osteoblasts by deleting the gene encoding RUBCN/Rubicon, a negative regulator of autophagy. The rubcnflox/flox;Sp7/Osterix-Cre mice showed progressive skeletal abnormalities in femur bones. Consistent with this, RUBCN deficiency in osteoblasts resulted in elevated differentiation and mineralization, as well as an increase in the elevated expression of key transcription factors involved in osteoblast function such as Runx2 and Bglap/Osteocalcin. Furthermore, RUBCN deficiency in osteoblasts accelerated autophagic degradation of NOTCH intracellular domain (NICD) and downregulated the NOTCH signaling pathway, which negatively regulates osteoblast differentiation. Notably, osteoblast-specific deletion of RUBCN alleviated the phenotype in a mouse model of osteoporosis. We conclude that RUBCN is a key regulator of bone homeostasis. On the basis of these findings, we propose that medications targeting RUBCN or autophagic degradation of NICD could be used to treat age-related osteoporosis and bone fracture.Abbreviations: ALPL: alkaline phosphatase, liver/bone/kidney; BCIP/NBT: 5-bromo-4-chloro-3'-indolyl phosphate/nitro blue tetrazolium; BMD: bone mineral density; BV/TV: bone volume/total bone volume; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MTOR: mechanistic target of rapamycin kinase; NICD: NOTCH intracellular domain; RB1CC1/FIP200: RB1-inducible coiled-coil 1; RUBCN/Rubicon: RUN domain and cysteine-rich domain containing, Beclin 1-interacting protein; SERM: selective estrogen receptor modulator; TNFRSF11B/OCIF: tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin).

Entities:  

Keywords:  Bone remodeling; NICD; RUBCN; Rubicon; differentiation; mineralization; osteoblast

Mesh:

Substances:

Year:  2022        PMID: 35025696      PMCID: PMC9542956          DOI: 10.1080/15548627.2021.2017587

Source DB:  PubMed          Journal:  Autophagy        ISSN: 1554-8627            Impact factor:   13.391


  40 in total

1.  Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors.

Authors:  Stephen J Rodda; Andrew P McMahon
Journal:  Development       Date:  2006-07-19       Impact factor: 6.868

2.  Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.

Authors:  Chad Deal; Molly Omizo; Elliott N Schwartz; Erik F Eriksen; Per Cantor; Jingyuan Wang; Emmett V Glass; Stephen L Myers; John H Krege
Journal:  J Bone Miner Res       Date:  2005-07-18       Impact factor: 6.741

3.  Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts.

Authors:  Volker Viereck; Carsten Gründker; Sabine Blaschke; Britta Niederkleine; Heide Siggelkow; Karl-Heinz Frosch; Dirk Raddatz; Günter Emons; Lorenz C Hofbauer
Journal:  J Clin Endocrinol Metab       Date:  2003-09       Impact factor: 5.958

4.  Notch inhibits osteoblast differentiation and causes osteopenia.

Authors:  Stefano Zanotti; Anna Smerdel-Ramoya; Lisa Stadmeyer; Deena Durant; Freddy Radtke; Ernesto Canalis
Journal:  Endocrinology       Date:  2008-04-17       Impact factor: 4.736

5.  Autophagy is essential for preimplantation development of mouse embryos.

Authors:  Satoshi Tsukamoto; Akiko Kuma; Mirei Murakami; Chieko Kishi; Akitsugu Yamamoto; Noboru Mizushima
Journal:  Science       Date:  2008-07-04       Impact factor: 47.728

6.  Suppression of autophagy by FIP200 deletion leads to osteopenia in mice through the inhibition of osteoblast terminal differentiation.

Authors:  Fei Liu; Fang Fang; Hebao Yuan; Dongye Yang; Yongqiang Chen; Linford Williams; Steven A Goldstein; Paul H Krebsbach; Jun-Lin Guan
Journal:  J Bone Miner Res       Date:  2013-11       Impact factor: 6.741

Review 7.  Autophagy in the pathogenesis of disease.

Authors:  Beth Levine; Guido Kroemer
Journal:  Cell       Date:  2008-01-11       Impact factor: 41.582

8.  Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice.

Authors:  Satoshi Tanaka; Hayato Hikita; Tomohide Tatsumi; Ryotaro Sakamori; Yasutoshi Nozaki; Sadatsugu Sakane; Yuto Shiode; Tasuku Nakabori; Yoshinobu Saito; Naoki Hiramatsu; Keisuke Tabata; Tsuyoshi Kawabata; Maho Hamasaki; Hidetoshi Eguchi; Hiroaki Nagano; Tamotsu Yoshimori; Tetsuo Takehara
Journal:  Hepatology       Date:  2016-10-21       Impact factor: 17.298

9.  Age-dependent loss of adipose Rubicon promotes metabolic disorders via excess autophagy.

Authors:  Tadashi Yamamuro; Tsuyoshi Kawabata; Atsunori Fukuhara; Shotaro Saita; Shuhei Nakamura; Hikari Takeshita; Mari Fujiwara; Yusuke Enokidani; Gota Yoshida; Keisuke Tabata; Maho Hamasaki; Akiko Kuma; Koichi Yamamoto; Iichiro Shimomura; Tamotsu Yoshimori
Journal:  Nat Commun       Date:  2020-08-18       Impact factor: 17.694

10.  Suppression of autophagic activity by Rubicon is a signature of aging.

Authors:  Shuhei Nakamura; Masaki Oba; Mari Suzuki; Atsushi Takahashi; Tadashi Yamamuro; Mari Fujiwara; Kensuke Ikenaka; Satoshi Minami; Namine Tabata; Kenichi Yamamoto; Sayaka Kubo; Ayaka Tokumura; Kanako Akamatsu; Yumi Miyazaki; Tsuyoshi Kawabata; Maho Hamasaki; Koji Fukui; Kazunori Sango; Yoshihisa Watanabe; Yoshitsugu Takabatake; Tomoya S Kitajima; Yukinori Okada; Hideki Mochizuki; Yoshitaka Isaka; Adam Antebi; Tamotsu Yoshimori
Journal:  Nat Commun       Date:  2019-02-19       Impact factor: 17.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.